Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine

被引：22

作者：

Nakagawa, K ^{[1
]}

Ishizaki, T ^{[1
]}

机构：

[1] Kumamoto Univ, Grad Sch Clin Pharm, Dept Pharmacol & Therapeut, Kumamoto 8620973, Japan

来源：

PHARMACOLOGY & THERAPEUTICS | 2000年 / 86卷 / 01期

关键词：

pharmacogenetics; polymorphism; cytochromes P-450 (CYPs); cardiovascular drugs; cardiovascular diseases; pharmacodynamics;

D O I：

10.1016/S0163-7258(99)00066-2

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The variability in the individual response to drugs may be due either to interindividual variations in the pharmacokinetics of the drugs or to the heterogeneity of the mechanism(s) underlying the diseases, or both. In both cases, genetic heterogeneity is involved in the metabolism of cardiovascular drugs and pathogenesis of inherited cardiovascular disorders. Molecular genetic technologies can now provide sensitive and efficient genetic testing, not only to identify polymorphic drug metabolism genes, but also to identify disease-associated genes for diagnosis and risk stratification of many hereditary cardiovascular diseases. In this review, we discuss the polymorphic metabolism of cardiovascular drugs and the molecular genetics of cardiovascular diseases in relation to the genes determining the responsiveness to a given drug. (C) 2000 Elsevier Science Inc. All rights reserved.

引用

页码：1 / 28

页数：28

共 360 条

[21]

Bianchi G, 1995, CLIN EXP PHARMACOL P, V22, pS399

[22] 2 POINT MUTATIONS WITHIN THE ADDUCIN GENES ARE INVOLVED IN BLOOD-PRESSURE VARIATION [J].

BIANCHI, G ;

TRIPODI, G ;

CASARI, G ;

SALARDI, S ;

BARBER, BR ;

GARCIA, R ;

LEONI, P ;

TORIELLI, L ;

CUSI, D ;

FERRANDI, M ;

PINNA, LA ;

BARALLE, FE ;

FERRARI, P .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :3999-4003

[23] A novel X-linked gene, G4.5. is responsible for Barth syndrome [J].

Bione, S ;

DAdamo, P ;

Maestrini, E ;

Gedeon, AK ;

Bolhuis, PA ;

Toniolo, D .

NATURE GENETICS, 1996, 12 (04) :385-389

[24] ANGIOTENSIN-II TYPE-1 RECEPTOR GENE POLYMORPHISMS IN HUMAN ESSENTIAL-HYPERTENSION [J].

BONNARDEAUX, A ;

DAVIES, E ;

JEUNEMAITRE, X ;

FERY, I ;

CHARRU, A ;

CLAUSER, E ;

TIRET, L ;

CAMBIEN, F ;

CORVOL, P ;

SOUBRIER, F .

HYPERTENSION, 1994, 24 (01) :63-69

[25] Familial hypertrophic cardiomyopathy from mutations to functional defects [J].

Bonne, G ;

Carrier, L ;

Richard, P ;

Hainque, B ;

Schwartz, K .

CIRCULATION RESEARCH, 1998, 83 (06) :580-593

[26] Metabolic ratios of four probes of CYP2D6 in Turkish subjects: A cross-over study [J].

Bozkurt, A ;

Basci, NE ;

Isimer, A ;

Sayal, A ;

Kayaalp, SO .

EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1996, 21 (04) :309-314

[27] Evaluation of the angiotensinogen locus in human essential hypertension - A European study [J].

Brand, E ;

Chatelain, N ;

Keavney, B ;

Caulfield, M ;

Citterio, L ;

Connell, J ;

Grobbee, D ;

Schmidt, S ;

Schunkert, H ;

Schuster, H ;

Sharma, AM ;

Soubrier, F .

HYPERTENSION, 1998, 31 (03) :725-729

[28] ASSESSMENT OF LIVER METABOLIC FUNCTION - CLINICAL IMPLICATIONS [J].

BROCKMOLLER, J ;

ROOTS, I .

CLINICAL PHARMACOKINETICS, 1994, 27 (03) :216-248

[29] THE METABOLISM OF MEXILETINE IN RELATION TO THE DEBRISOQUINE SPARTEINE-TYPE POLYMORPHISM OF DRUG OXIDATION [J].

BROLY, F ;

VANDAMME, N ;

LIBERSA, C ;

LHERMITTE, M .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (04) :459-466

[30] Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation [J].

Burchell, B ;

Coughtrie, MWH .

ENVIRONMENTAL HEALTH PERSPECTIVES, 1997, 105 :739-747

← 1 2 3 4 5 6 7 8 9 10 →